SYRE
Spyre Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Fund move
Fund move
Last report1 of 7 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
−0.56%
vs ±13.8% implied · ×0.04
shaded = implied · ▲▼ = realized
Spyre Therapeutics, Inc.
96.44
No thesis.
| Rank | Manager | Value | % 13F | ||
|---|---|---|---|---|---|
| 1 | FMRFMR | $1.2B | 13.48% | +10.57% | |
| 2 | BlackRockBlackRockindex-like | $577.7M | 6.73% | +17.85% | |
| 3 | Perceptive AdvisorsPerceptive | $383.5M | 4.47% | +14.17% | |
| 4 | RTW InvestmentsRTW | $377.5M | 4.40% | +1.92% | |
| 5 | Paradigm Biocapital AdvisorsParadigm Biocapital | $341.0M | 3.97% | +96.23% | |
| 6 | Vanguard Capital ManagementVanguardindex-like | $306.2M | 3.57% | +12.80% | |
| 7 | State StreetState Streetindex-like | $271.4M | 3.16% | +17.28% | |
| 8 | VR AdviserVR Adviser | $265.0M | 3.09% | −18.99% | |
| 9 | T. Rowe Price AssociatesT. Rowe Price | $262.9M | 3.06% | +85.20% | |
| 10 | Driehaus Capital ManagementDriehaus | $248.5M | 2.90% | +0.30% | |
| 11 | Geode Capital ManagementGeodeindex-like | $239.3M | 2.79% | +48.89% | |
| 12 | Vanguard Portfolio ManagementVanguard Portfolioindex-like | $206.9M | 2.41% | +298.22% | |
| 13 | Capital World InvestorsCapital World Investors | $205.6M | 2.40% | +247.39% | |
| 14 | Jupiter TopcoJupiter Topco | $195.9M | 2.28% | — | |
| 15 | TCG Crossover ManagementTCG Crossover | $168.7M | 1.97% | 0.00% | |
| 16 | Tang Capital ManagementTang | $168.0M | 1.96% | 0.00% | |
| 17 | Bank of AmericaBank of America | $157.8M | 1.84% | +44.77% | |
| 18 | Adage Capital Partners GPAdage Capital Partners GP | $152.9M | 1.78% | new | |
| 19 | Wellington Management GroupWellington | $140.4M | 1.64% | −13.33% | |
| 20 | Goldman Sachs GroupGoldman Sachs | $131.2M | 1.53% | +447.55% | |
| 21 | Franklin ResourcesFranklin Resources | $130.8M | 1.52% | +66.84% | |
| 22 | Remedium Capital PartnersRemedium Capital Partners | $130.0M | 1.52% | −23.23% | |
| 23 | Affinity Asset AdvisorsAffinity Asset | $113.6M | 1.32% | 0.00% | |
| 24 | JPMorgan ChaseJPMorgan Chase | $98.9M | 1.15% | +11.61% | |
| 25 | Holocene AdvisorsHolocene | $90.1M | 1.05% | new |
266 managers report $8.6B of Spyre Therapeutics on form 13F for the quarter ended Jun 30 '26. 29 of them hold 80% of it; FMR is largest at 13.48%.
Expected move
Inputs8Q avg ±5.6%·×1.47·rich
straddle ±12.9%
spot 96.56exp Nov 20ATM strike 95ATM straddle 14.70IV 80%